Gentile Kimberly 4

What Happened Kimberly Gentile, Senior Vice President, Clinical Operations at Biohaven Ltd. (BHVN), received a grant of derivative securities covering 175,000 shares on February 27, 2026. The Form 4 reports the acquisition at $0.00 (an equity award/option-type grant), not a market purchase or sale. The award is reported as a derivative acquisition rather than an open-market transaction.

Key Details

• Transaction date and filing: Transaction dated 2026-02-27; Form 4 filed 2026-03-03 (timely within required business-day window).
• Securities: 175,000 derivative shares reported as acquired at $0.00.
• Vesting: Per footnote, the shares underlying this option vest in four equal installments on Feb 27 of 2026, 2027, 2028 and 2029, subject to continuous service.
• Shares owned after transaction: Not specified in this filing.
• Transaction code: A (award/grant of derivative securities).

Context This was a compensation-related equity award (derivative grant) that vests over four years rather than an immediate purchase or sale. Such grants are common for executives and staff as retention/compensation and do not by themselves indicate immediate buying or selling sentiment. Because the award vests over time, the economic benefit to the insider depends on continued service and any future exercise terms (exercise price, expiration) not detailed in the summarized fields.